Indianapolis-based ApeX Therapeutics has rebranded itself. The company, now known as Apexian Pharmaceuticals Inc., says the name change better reflects its broader advancement of cancer-fighting medicines.
The rebranding comes weeks after the company announced Steve Carchedi as its new chief executive officer. Carchedi is the former CEO of New Jersey-based Cornerstone Pharmaceuticals. He says the name change is indicative of the "great progress" the company has made.
"Now is the time to acknowledge that our key priorities are increasingly focused on advancing our innovative oncology molecules through the clinic," said Carchedi. "We are committed to developing innovative new medicines to extend and enhance the lives of cancer patients."
Apexian says it expects to begin clinical studies later this year of a new drug that is being developed to treat late-stage cancer.